Promethazine vs. Codeine – a quick comparison
| Feature | Promethazine | Codeine |
|---------|------------------|-------------|
| Drug class | First‑generation antihistamine (H1 antagonist) with strong anticholinergic and anti‑emetic properties. | Opioid analgesic (a mild to moderate μ‑opioid receptor agonist). |
| Primary uses | • Allergy relief (urticaria, allergic rhinitis)
• Drowsiness/sedation (pre‑operative, postoperative, insomnia)
• Anti‑emetic (motion sickness, postoperative nausea)
• Anti‑nausea in chemotherapy
• Some cough suppressants (when combined with an opioid). | • Moderate to severe pain (post‑operative, trauma, chronic pain)
• Cough suppression (in some cough syrups)
• Mild to moderate analgesic when used alone. |
| Mechanism of action | Blocks H1 histamine receptors → ↓ allergy symptoms; blocks central cholinergic pathways → ↓ nausea; also has sedative effect via GABAergic modulation. | Pro‑drug; converted by CYP2D6 to morphine → activates μ‑opioid receptors → ↓ pain perception, induces cough suppression. |
| Onset / Duration | Rapid (5–10 min IV/IM, ~20–30 min PO); short‑acting (4–6 h). | Slower onset (30 min PO), lasting 4–6 h; can be prolonged if metabolized to morphine. |
| Side‑effect profile | • Sedation, drowsiness, hypotension (especially when combined with other CNS depressants).
• Anticholinergic: dry mouth, blurred vision, urinary retention, constipation.
• Rarely paradoxical agitation or delirium in children.
• Black‑box warning for respiratory depression when co‑administered with opioids. | • Respiratory depression (most serious risk).
• Sedation, dizziness, nausea.
• Constipation (opioid‑related).
• Potential for abuse, dependence, withdrawal. |
| Drug interactions | • Potentiates CNS depressants (benzodiazepines, alcohol, opioids).
• CYP2D6 inhibitors (fluoxetine, paroxetine) may increase promethazine levels.
• Anticholinergics (e.g., atropine, antihistamines) can compound dry‑mouth or constipation. | • CYP2D6 inhibitors (fluoxetine, paroxetine) decrease morphine formation → lower analgesic effect.
• CYP2D6 inducers (rifampin) increase morphine formation → higher risk of respiratory depression.
• Additive CNS depression when combined with alcohol, benzodiazepines, or other opioids. |
| Regulatory status | OTC in many countries for mild allergy or nausea, but prescription‑only for stronger indications (e.g., pre‑medication in anesthesia). | Schedule II controlled substance in the U.S. (and similar controls elsewhere). Prescription‑only. |
| Abuse potential | Low. Promethazine is not an addicting drug. | High. Codeine is a narcotic; misuse can lead to dependence and respiratory depression. |
| Typical formulations | Oral tablets, syrups, nasal sprays, IV/IM injections. | Oral tablets, capsules, syrups, extended‑release preparations. |
---
Bottom line
- Promethazine is a non‑opioid antihistamine mainly used for allergies, sedation, and anti‑emesis. It has strong anticholinergic effects and can cause sedation but is not addictive.
- Codeine is an opioid analgesic that works by being converted to morphine. It relieves pain and suppresses cough but carries significant risks of respiratory depression, constipation, and potential for addiction.
Because of these differences, clinicians choose each drug based on the problem being treated: allergy or nausea → promethazine; pain or moderate cough → codeine (often only after other treatments have failed). Always follow dosing instructions, watch for interactions, and keep in mind that codeine’s controlled‑substance status requires a prescription and careful monitoring.